Clinical trial
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial…
NCT00478426 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00478426 |
|---|---|
| Title | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer |
| Official title | A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7, Uterine Carcinosarcoma, Uterine Corpus Carcinosarcoma |
| Intervention type | Drug |
| Interventions | Sunitinib Malate |
| Enrollment | 34 |
| Start date | Apr 30, 2007 |
| Primary completion | Feb 12, 2019 |
| Completion | Feb 12, 2019 |
| First posted | May 24, 2007 |
| Last update posted | Feb 17, 2020 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: